Drug pricing reform in China: analysis of piloted approaches and potential impact of the reform

References

• OECD. Health expenditure and financing: Health expenditure indicators. OECD Health Statistics (database). 2015. Available from: http://www.oecd-ilibrary.org/social-issues-migration-health/data/oecd-health-statistics/system-of-health-accounts-health-expenditure-by-function_data-00349-en [cited 20 June 2015].
   Google Scholar
• McKinsey & Company. Healthcare in China: ‘Entering uncharted waters’. 2014. Available from: http://www.mckinsey.com/~/media/mckinsey/dotcom/client_service/pharma and medical products/pmp new/pdfs/healthcare_in_china-entering_uncharted_waters.ashx [cited 10 June 2015].
   Google Scholar
• The World Bank. World development indicators, China. 2015. Available from: http://data.worldbank.org/country/china?display=default [cited 20 June 2015].
   Google Scholar
• IMS Health. IMS pharmaceutical pricing & reimbursement concise guide: China. 2014; IMS Health.
   Google Scholar
• Long Q, Xu L, Bekedam H, Tang S. Changes in health expenditures in China in 2000s: Has the health system reform improved affordability. Int J Equity Health. 2013; 12: 40. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• OECD/WHO. Pharmaceutical expenditure, in OECD/WHO. 2012; Paris: OECD Publishing. Available from: http://dx.doi.org/10.1787/9789264183902-32-en [cited 26 June 2015] Health at a Glance: Asia/Pacific 2012.
   Google Scholar
• Li Y, Xu J, Wang F, Wang B, Liu L, Hou W, etal. Overprescribing in China, driven by financial incentives, results in very high use of antibiotics, injections, and corticosteroids. Health Affairs. 2012; 31: 1075–82. [PubMed Abstract].
   Google Scholar
• Eggleston K, Ling L, Qingyue M, Lindelow M, Wagstaff A. Health service delivery in China: a literature review. Health Econ. 2008; 17: 149–65. [PubMed Abstract].
   Google Scholar
• Brixi H, Mu Y, Targa B, Hipgrave D. Engaging sub-national governments in addressing health equities: Challenges and opportunities in China health system reform. Health Pol Plann. 2013; 28: 809–24.
   Google Scholar
• Health Development Outlook. [Urban and rural health inequalities remained a concern]. 2014. Available from: http://www.cchds.pku.edu.cn/attachments/article/269/Health Development Outlook-13.pdf [cited 26 June 2015].
   Google Scholar
• CPC Central Committee State Council. [Opinion on deepening healthcare reform]. 2009. Available from: http://www.gov.cn/jrzg/2009-04/06/content_1278721.htm [cited 12 June 2015].
   Google Scholar
• Yanfeng G. [Chinese medical reform progress and direction for the next step]. 2013. Available from: http://chinado.cn:8080/ReadNews.asp?NewsID = 2939 [cited 6 June 2015].
   Google Scholar
• National Development and Reform Commission. [Abolishment of government (guided) pricing for the majority of drugs and push to the drug pricing reform]. 2015. Available from: http://www.sdpc.gov.cn/xwzx/xwfb/201505/t20150505_690687.html [cited 10 June 2015].
   Google Scholar
• WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies. Glossary 2015. Available from: http://whocc.goeg.at/Glossary/About [cited 12 April 2015]..
   Google Scholar
• Carone G, Schwierz C, Xavier A. Cost-containment policies in public pharmaceutical spending in the EU. European Commission-European Economy. 2012. Economic Paper 461: 461.
   Google Scholar
• Dylst P, Vulto A, Simoens S. Reference pricing systems in Europe: Characteristics and consequences. Generics Biosimilars Initiative J. 2012; 1: 127–31.
   Google Scholar
• Galizzi MM, Ghislandi S, Miraldo M. What do we really know about reference pricing for pharmaceuticals?. Eurohealth. 2011; 17: 17–9.
   Google Scholar
• Bouvy J, Vogler S. Pricing and Reimbursement Policies: Impacts on Innovation. Background Paper 8.3 for the Priority Medicine for Europe and the World Update Report, 2013. 2013; Geneva;: WHO.
   Google Scholar
• Toumi M, Remuzat C, Vataire A-L, Urbinati D. External reference pricing of medicinal products: Simulation-based considerations for cross-country coordination. 2014. Available from: http://ec.europa.eu/health/healthcare/docs/erp_reimbursement_medicinal_products_en.pdf [cited 15 June 2015].
   Google Scholar
• NewsChina. [Influence from abolishment of government (guided) pricing]. 2015. Available from: http://news.china.com/jiedu/20150505/ [cited 26 June 2015].
   Google Scholar
• Jiangsu Province Pharmaceutical Alliance. [Summary of yesterday's national meeting of reference price (for drugs in the health insurance formulary)]. 2015. Available from: http://article.haoxiana.com/176240.html [cited 18 June 2015].
   Google Scholar
• Great Wisdom Finance and Economics (Shanghai). [Sanming Healthcare reform: the reference price will set at the cheapest domestic generic to decrease drug prices]. 2014. Available from: http://www.sm.gov.cn/ztzl/shyywstzgg/mtbd/201410/t20141011_274086.htm [cited 12 June 2015]..
   Google Scholar
• Xinhua News Agency. [Secret: Sanming healthcare reform, how to succeed?]. 2015. Available from: http://www.sm.gov.cn/ztzl/shyywstzgg/gzdt/201502/t20150208_285631.htm [cited 10 June 2015]..
   Google Scholar
• Chongqing Municipal People's Government Office. [Notification of the implementation of drugs payment standard for drugs within Reimbursement Drug List (Trial)]. 2015. Available from: http://www.baiduyy.com/zbxx/zbxx_xx_30203.htm [cited 10 June 2015].
   Google Scholar
• Chongqing Municipal Human Resources and Social Security Bureau. [Establishment of Chongqing drug price plan for drugs within the Reimbursement Drug List]. 2014. Available from: http://www.vchale.com/ypzbxx_com/201799193_1_ce22cc8d14fd4f0c9417f77826c30da9.html [cited 10 June 2015].
   Google Scholar
• Yiyaojie.com. [Shaoxing innovative pilot program in public healthcare institutions and centralized drug procurement and pricing mechanism (draft)]. 2014. Available from: http://www.yiyaojie.com/zb/zbzc/20141204/63824.html [cited 10 June 2015].
   Google Scholar
• Yangming Situ.2015. [14 imported drugs have been stopped or restricted to use in Shaoxing Tier 3 hospitals]. Available from: http://www.chinamsr.com/2015/0130/83929.shtml [cited 10 June 2015]..
   Google Scholar
• Anhui Provincial Health and Family Planning Commission. [Notification of Anhui drug price caps for Reimbursement Drug List (reimbursement reference price) directory]. 2015. Available from: http://www.ahyycg.cn/HomePage/ShowDetail.aspx?InfoId=1020 [cited 12 April 2015].
   Google Scholar
• State Council. [State Council guidance on improving public hospitals centralized drug procurement]. 2015. Available from: http://www.gov.cn/zhengce/content/2015-02/28/content_9502.htm [cited 20 June 2015].
   Google Scholar
• Medicine Cloud Information. [1/4 of the cities might conduct the 2nd price negotiation, pharmaceutical companies entered the era of price negotiation]. 2015. Available from: http://www.yiyaojie.com/zb/zbzc/20150307/74192.html [cited 29 June 2015].
   Google Scholar
• China Eco Net. [Arguments on 2nd pricing, many areas releasing ‘yes’ signal]. 2015. Available from: http://finance.ce.cn/rolling/201506/04/t20150604_5543625.shtml [cited 27 January 2015]..
   Google Scholar
• Zhang X, Gong S. [The impact of health expenditure structure from public finance on the efficiency of health resource allocation]. Lingnan J. 2014; 101–6.
   Google Scholar
• Kou Z. [The relation between “hospital revenue relies on drugs dispensing” and “the difficult and expensive healthcare”]. World Econ. 2010; 33: 49–68.
   Google Scholar
• McKinsey & Company. China's health care reforms. 2010. Available from: http://www.mckinsey.com/~/media/mckinsey/dotcom/client_service/healthcare systems and services/health international/hi10_china_healthcare_reform.ashx [cited 10 June 2015].
   Google Scholar
• Song Y, Bian Y, Petzold M, Li L, Yin A. Effects of the national essential medicine system in reducing drug prices: An empirical study in four Chinese provinces. J Pharm Policy Pract. 2014; 7: 12. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Li Y, Ying C, Sufang G, Brant P, Bin L, Hipgrave D. Evaluation, in three provinces, of the introduction and impact of China's National Essential Medicines Scheme. Bull World Health Organ. 2013; 91: 184–94. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Li C. Telmisartan tablets: Research on quality differences of generics and the original drugs. PhD thesis. 2013; Central South University, Changsha, China.
   Google Scholar
• Wang B, Zhang C, Mei D. [Comparative study on clarithromycin produced by different manufacturers: The preparations, related substances and dissolution]. Chin Pharmaceut J. 2014; 49: 1933–8.
   Google Scholar
• Li J, Wang Y, Song Y, Fan H, Ding L, Du G. Low molecular weight heparin injections quality evaluation. Chin J Pharmaceut Anal. 2013; 38: 1768–73.
   Google Scholar
• China Food and Drug Administration. [Notice 2015 No. 3: oral solid dosage dissolution test technical guidelines and technical guidelines for the chemical stability of the drug pharmaceutical raw materials and formulations)]. 2015. Available from: http://www.sfda.gov.cn/WS01/CL1236/114286.html [cited 15 June 2015].
   Google Scholar
• Barber SL, Huang B, Santoso B, Laing R, Paris V, Wu C. The reform of the essential medicines system in China: A comprehensive approach to universal coverage. J Global Health. 2013; 3: 1–9.
   Web of Science ®Google Scholar
• National Institute for Food and Drug Control. [Work in progress]. 2015. Available from: http://www.nifdc.org.cn/fzy/CL0622/ [cited 21 June 2015].
   Google Scholar
• Daems R, Maes E, Ramani S. Global Framework for differential pricing of pharmaceuticals. 2011; Maastricht;: United Nations University and Maastricht University.
   Google Scholar
• China Economic Net. [After market pricing, with drug prices fall?]. 2015. Available from: http://opinion.china.com.cn/opinion_5_129105.html [cited 2 June 2015].
   Google Scholar
• Shaoxing Sunshine Network. [In Shaoxing nearly 100 kinds of drugs disappear from hospitals, patients need to go to buy expensive drugs from private pharmacies]. 2015. Available from: http://toutiao.com/a4501041396/ [cited 10 June 2015].
   Google Scholar
• HC Pharmaceutical Industry Network. [The 2nd price negotiation: Drugs will be stopped if do not accept the price decreasing]. 2015. Available from: http://info.pharmacy.hc360.com/2015/01/210952545605.shtml [cited 15 June 2015].
   Google Scholar